Big Pharma's EU Woes Continued In Second Quarter - Where’s The Bottom?
Executive Summary
In addition to patent expiries, which affected pharma company performance globally, ongoing price cuts for drugs and increasing parallel trade continued to hurt pharma’s European performance in the second quarter, with the gloom unlikely to lift soon. What’s at stake is further pharma investment in Europe.
You may also be interested in...
AirFluSal’s Decentralized Approach to EU Shields Seretide From Exposure
Sandoz’ AirFluSal Forspiro has been approved in Germany, but the company’s decentralized route into Europe means that GSK’s Seretide is somewhat shielded from all-out competition.
Second-Quarter Earnings Updates, In Brief
In quarterly earnings calls, GlaxoSmithKline talks acquisition strategy while Regeneron is bullish on the sales prospects for its age-related macular degeneration drug Eylea and Sanofi highlights the recently initiated Phase III ODYSSEY program in hypercholesterolemia.
J&J Under CEO Gorsky Will Remain Diverse But Be More Selective
New CEO Alex Gorsky outlines his vision for the healthcare giant in his first quarterly sales and earnings presentation to investors. Short-term priorities include restoring OTC drug supply and building pharmaceutical sales momentum.